Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2018

View Archived Issues

CRISPR: shoddy repairs?

Vasopressin inhibition decreases mortality in jet-lagged mice

Grant supports Poseida's late-stage preclinical development of P-PSMA-101

Koutif Therapeutics completes IND-enabling studies with Fbxo3 inhibitor KT-1002

Imugene advances preclinical development of new PD-1 cancer vaccine KEY-Vaxx

FDA approves Pfizer's filgrastim biosimilar Nivestym

Regen BioPharma's lead NR2F6 small-molecule agonist RG-NAE005 shows no toxicity in mice

NAMPT knockdown attenuates acute lung injury in mice models by upregulation of SFTPB expression

Data reported for gantenerumab in Alzheimer's disease from SCarlet RoAD and Margeurite RoAD studies

Anima and Lilly collaborate to discover and develop translation inhibitors to target proteins

Bridge Medicines and Memorial Sloan Kettering partner on platform to deliver drugs to kidneys

Isogenica licenses CIS Display technology to Aro Biotherapeutics for drug development

PharmaCyte completes stability study of Cell-in-a-Box encapsulated cells for pancreatic cancer

Reata reports promising phase II data from bardoxolone trials in chronic kidney disease

Preclinical results presented for SUVN-I2004, Suven Life Sciences' M1 receptor PAM lead candidate

Addition of sodium thiosulfate to cisplatin lowers incidence of cisplatin-induced hearing loss

let-7b as a novel biomarker of Graves' disease

Stanford University AI system predicts side effects of drug combinations

BCL-3 confers resistance to alkylating therapy in patients with gliomas

Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine patent oxytocin receptor antagonists

Medshine Discovery identifies new EGFR inhibitors

Phase III study of Revlimid in relapsed/refractory indolent lymphoma meets primary endpoint

Active substance in ROSgard protects kidney tissue in preclinical acute kidney injury study